Assess whether biosimilarity is analytically justified (cc9241)

Situation

Clinical and Evidence Strategy work in a safety team sitting on a new disproportionate signal now turns on biosimilarity is analytically justified because a literature paper the 505(b)(2) package leans on getting retracted put complete-response-letter deficiency list in play. CMC change-control owner should say what complete-response-letter deficiency list proves.

Decision

CMC change-control owner in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using complete-response-letter deficiency list after a literature paper the 505(b)(2) package leans on getting retracted.

Hypotheses to test

• Complete-response-letter deficiency list reads as Proceed under protocol once a literature paper the 505(b)(2) package leans on getting retracted is lined up to the same Pharma & Life Sciences population.
• Complete-response-letter deficiency list is closer to Pause the pathway after a literature paper the 505(b)(2) package leans on getting retracted; Proceed under protocol would over-claim this Clinical and Evidence Strategy extract.
• Escalate safety review is still live in complete-response-letter deficiency list for CMC change-control owner in a safety team sitting on a new disproportionate signal.
• Complete-response-letter deficiency list is missing the fact CMC change-control owner needs after a literature paper the 505(b)(2) package leans on getting retracted; stop this Pharma & Life Sciences close.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• Check whether complete-response-letter deficiency list supports the labeled claim CMC change-control owner would keep.
• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read complete-response-letter deficiency list against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move biosimilarity is analytically justified for CMC change-control owner.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (complete-response-letter deficiency list after a literature paper the 505(b)(2) package leans on getting retracted). Lead with the Pharma & Life Sciences option complete-response-letter deficiency list can support after a literature paper the 505(b)(2) package leans on getting retracted, then the two facts that force it, then the Monday action for CMC change-control owner in a safety team sitting on a new disproportionate signal.